Clinical Trial Results:
A phase 2a study to evaluate the effect of rilapladib (SB-659032)
on biomarkers related to the pathogenesis and progression of
Alzheimer’s disease.
Summary
|
|
EudraCT number |
2010-020993-41 |
Trial protocol |
DE SE NO ES IT |
Global completion date |
18 Feb 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 Feb 2016
|
First version publication date |
06 Nov 2014
|
Other versions |
|
Summary report(s) |
114458-Clinical-Study-Result-Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.